Global HDL Cholesterol Kits Market Overview:
With technological advances that are penetrating deeper into health systems, a radical transition has taken place in the field of diagnostics from a "lengthy" process to "ready in seconds" results. Similarly, high-density lipoproteins (HDL) cholesterol kits have received considerable attention in laboratories and healthcare and offer specialized services for risk assessment of cardiovascular diseases (CVD). In addition, a growing trend in point-of-care testing and self-testing with point-of-care cholesterol monitors is likely to benefit HDL cholesterol kit sales. These kits measure HDL cholesterol levels in plasma or serum samples. Provides enough reagents, including blanks, cholesterol standards, and unknown samples, to perform 96 assays.
- Increasing Incidence of Cardiovascular Diseases and Obesity
- Government Initiatives to Improve Quality of Testing Kits
- Increasing Prevalence of Dyslipidemia Due to Obesity and Diabetes
- Rapid Growth in the Geriatric Population
- A Rising Trend of Point-Of-Care Testing and Self-Testing
- Advanced Healthcare Systems
- Increasing Healthcare Screening Initiatives
- Competition among the Players
- Availability of Other Substitutes For Testing
- Increasing Number of Awareness Programs Encouraging People to Actively Go For Cholesterol Testing
- Manufacturers Are Targeting New Launches in the Point-Of-Care HDL Cholesterol Kits Category
- Lack of Awareness about the HDL Cholesterol Kits
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Roche (Switzerland), Abbott Laboratories (United States), Danaher (United States), Thermo Fisher Scientific (United States), Merck & Co. (United States), Abcam (United Kingdom), Fujifilm (Japan), PerkinElmer (United States), Diazyme Laboratories (United States) and Randox Laboratories (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like Sekisui Diagnostics (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global HDL Cholesterol Kits market by 2025. Considering Market by Kit Components, the sub-segment i.e. Microtiter Plate will boost the HDL Cholesterol Kits market. Considering Market by Distribution Channel, the sub-segment i.e. OEMs will boost the HDL Cholesterol Kits market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global HDL Cholesterol Kits market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in HDL Cholesterol Kits market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of HDL Cholesterol Kits, Suppliers and Distributors of HDL Cholesterol Kits, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.